Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10940
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSeeman, Egoen
dc.contributor.authorBoonen, Stevenen
dc.contributor.authorBorgström, Frederiken
dc.contributor.authorVellas, Brunoen
dc.contributor.authorAquino, Jean-Pierreen
dc.contributor.authorSemler, Juttaen
dc.contributor.authorBenhamou, Claude-Laurenten
dc.contributor.authorKaufman, Jean-Marcen
dc.contributor.authorReginster, Jean-Yvesen
dc.date.accessioned2015-05-16T00:31:04Z-
dc.date.available2015-05-16T00:31:04Z-
dc.date.issued2009-12-21en
dc.identifier.citationBone 2009; 46(4): 1038-42en
dc.identifier.govdoc20026265en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10940en
dc.description.abstractLongevity has resulted in a greater proportion of the population entering a time of life when increasing bone fragility and falls predispose to fractures, particularly nonvertebral fractures. Women over 80 years of age constitute 10% of the population but contribute 30% of all fractures and 60% of all nonvertebral fractures. Despite this, few studies have examined antifracture efficacy of treatments in this high-risk group and none has provided evidence for benefits beyond 3 years.To determine whether strontium ranelate reduces the risk of vertebral and nonvertebral fractures during 5 years, we analyzed a subgroup of 1489 female patients over 80 years of age (mean 83.5+/-3.0 years) with osteoporosis from the SOTI (spinal osteoporosis therapeutic intervention) and TROPOS (treatment of peripheral osteoporosis) studies randomized to strontium ranelate 2 g/d or placebo. All received a supplement of calcium plus vitamin D.By intention to treat, vertebral fracture risk was reduced by 31% (relative risk, RR=0.69; 95% confidence interval, CI 0.52-0.92), nonvertebral fracture risk by 27% (RR=0.73; 95% CI 0.57-0.95), major nonvertebral fracture risk by 33% (RR=0.67; 95% CI 0.50-0.89) and hip fracture risk by 24% (RR=0.76; 95% CI 0.50-1.15, not significant). Treatment was cost-saving as it decreased cost and increased QALYs and life-years.Strontium ranelate safely produced a significant reduction in vertebral and nonvertebral fracture risk during 5 years in postmenopausal women over 80 years of age and was cost saving.en
dc.language.isoenen
dc.subject.otherAged, 80 and overen
dc.subject.otherBone Density.drug effectsen
dc.subject.otherBone Density Conservation Agents.therapeutic useen
dc.subject.otherBone and Bones.drug effectsen
dc.subject.otherCalcium, Dietary.therapeutic useen
dc.subject.otherFemaleen
dc.subject.otherHip Fractures.prevention & controlen
dc.subject.otherHumansen
dc.subject.otherIntention to Treat Analysisen
dc.subject.otherOrganometallic Compounds.therapeutic useen
dc.subject.otherOsteoporosis, Postmenopausal.drug therapyen
dc.subject.otherQuality of Lifeen
dc.subject.otherSpinal Fractures.prevention & controlen
dc.subject.otherThiophenes.therapeutic useen
dc.subject.otherTreatment Outcomeen
dc.titleFive years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age.en
dc.typeJournal Articleen
dc.identifier.journaltitleBoneen
dc.identifier.affiliationAustin Health, University of Melbourne, Melbourne, Australiaen
dc.identifier.doi10.1016/j.bone.2009.12.006en
dc.description.pages1038-42en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/20026265en
dc.type.austinJournal Articleen
local.name.researcherSeeman, Ego
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptEndocrinology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

22
checked on Mar 29, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.